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Abstract
Introduction
Infective endocarditis (IE) was ﬁ rst described in 1885 by 
William Osler as infection of the heart valves in individuals 
with rheumatic valve disease.1 IE is now a major cause 
of morbidity and mortality with an annual incidence of 
approximately 3–10 cases per 100,000 patients and an in-
hospital mortality of 20%.2–5 More recently, there has been 
a marked change in the aetiology and demographics of IE 
globally.6 Historically associated with oral streptococcal 
infections, IE is now most commonly associated with 
healthcare-acquired infections; Staphylococcus aureus being 
the most common causative organism in the industrialised 
world.2,3,7 Degenerative valve disease, diabetes, malignancy, 
intravenous drug use and congenital heart disease are major 
risk factors for developing IE.6 Clinical presentation of IE can 
often vary between individuals, with fever (90%) and cardiac 
murmurs (85%) being the most common presenting features, 
and cardiac failure and embolic phenomena being the more 
commonly encountered complications.6,8,9 S. aureus often 
affects the native valves (70–80%) with left-sided valves 
being the most commonly targeted sites.10 The outcome 
of S. aureus native valve IE is worse than non-S. aureus 
infections.11 Mortality associated with left-sided S. aureus 
endocarditis ranges between 30 and 71%, and has remained 
high despite better diagnostic procedures, antimicrobial 
drugs and surgical intervention.12 Comparatively, right-sided 
IE has lower mortality, reported at 17%.12 IE commonly occurs 
in persons who inject drugs (PWID) with an annual incidence 
of 2–5%, usually affecting a younger age group compared to 
non-PWID IE.13–17 S. aureus is the most frequently (over 50%) 
isolated pathogen in this group.13,18–22 Approximately 10% IE 
involves the right-sided valves, of which the majority occur 
amongst PWID.23
More recently, there has been international concern about 
the growing use of ‘new psychoactive substances’ (NPS). 
Informally termed ‘designer drugs’ or ‘legal highs’, their 
widespread availability resulted in an alarming increase 
in use throughout Europe in 2014 as documented in the 
recent annual report from the European Monitoring Centre 
for Drugs and Drug Addiction.24 Up to 8% of individuals aged 
15–24 years have used NPS in the UK according to recent 
data from United Nations Ofﬁ ce on Drugs and Crime.24 More 
than 450 substances are currently being monitored by the 
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European Union Early Warning System.25 NPS use is an 
emerging social and medical problem in the UK.26 In 2012, 
52 deaths in England and Wales were directly attributable 
to NPS use.27,28 Unfortunately, ‘legal highs’ initially fell 
outside the drug regulatory laws and escaped legislative 
bans as they were engineered to evade existing regulations. 
Furthermore, the ease of availability of these substances 
over the internet, in retail outlets known as ‘head shops’ 
and with local drug suppliers allowed rapid distribution 
within communities. 
Most NPS are derived from synthetic cathinones and 
cannabinoids and can be classed into several categories, 
a few being sedatives, hallucinogens and stimulants.29 ‘Bath 
salts’ are a stimulant form of NPS and contain one or more 
synthetic derivatives of the naturally occurring cathinone, 
which targets plasma membrane monoamine transporters 
expressed on nerve cells and other cell types.30 These NPS 
inﬂ uence the uptake of several neurotransmitters, such 
as norepinephrine, dopamine and 5-hydroxytryptamine.31 
These products have no legitimate use as bath additives 
and are often labelled as ‘not for human consumption’ to 
circumvent laws governing their sale.30 The emergence of 
‘bath salts’ was ﬁ rst described in 2010 in the USA, and 
by 2011 a dramatic spike in emergency admissions with 
toxic exposures was seen. Patients intoxicated with ‘bath 
salts’ can present with severe and prolonged symptoms, 
including psychosis, combative behaviour, tachycardia 
and hyperthermia. A recent case series on cathinone-
related emergency admissions showed that 51% of these 
patients were admitted to hospital and 21% of these cases 
required critical care input.32,33 Infective complications can 
often occur at the site of injection and include cellulitis, 
abscesses or necrotising soft tissue infections. Blood 
stream infections are also common and can be associated 
with deeper infection, such as deep organ abscesses or 
complications including IE.34
Among PWID presenting with fever, 13% will have 
echocardiographic features suggestive of IE35 with S. aureus 
being the most common pathogen.7 Drug users have a higher 
rate of colonisation with S. aureus, which in turn, is a risk 
factor for infection and subsequent IE.36 
A possible association between ‘bath salt’ injecting and 
S. aureus cardiac infection has been described in New 
York, USA.17 A similar phenomenon has been observed in 
Lothian, Scotland, where a major increase in NPS injecting, 
particularly ethylphenidate-based ‘bath salts’, rapidly became 
a public health and public order issue in 2014 and 2015. 
The association in Lothian with a sharp increase in S. aureus 
bacteraemia has been published previously,34 but, alarmingly, 
many instances of S. aureus bacteraemia were associated 
with an underlying diagnosis of IE. We report an increased 
annual incidence of S. aureus-associated IE as a result of a 
change in drug-taking behaviour within a large Scottish health 
board (NHS Lothian), and describe differences in clinical 
progression within this group when compared to the same 
disease in a non-PWID group. 
Methods
Objectives
To compare presentations and outcomes of a cluster of 
S. aureus endocarditis associated with NPS with a series 
of S. aureus IE cases in a non-injecting population within a 
Scottish regional health authority covering a population of 
850,000 from 2014 to 2016.
Design, setting and participants
The prospective component of the study was carried out 
between 1 January 2014 and 31 May 2016 in a single 
Scottish Health Authority, which has three acute adult 
hospitals covering a population of 850,000. Cases were 
deﬁ ned as PWID who gave a recent history of injecting NPS 
and who were diagnosed as having S. aureus IE deﬁ ned by 
the Duke criteria.37 Data relating to PWID infections were 
collected and collated prospectively as part of a public 
health investigation of infections associated with injection 
of NPS. The control series consisted of all cases of S. aureus 
endocarditis diagnosed in a non-PWID population. These 
cases were also deﬁ ned using the Duke criteria and were 
derived from the same health authority region between 
2007 and 2016. A total of 14 S. aureus IE cases in a non-
PWID population were identiﬁ ed retrospectively. Electronic 
case records were used to collate patient demographics, 
antimicrobial treatment, investigations and clinical outcomes, 
including duration of in-patient care, surgical interventions 
performed and mortality at 90 days (from the date of 
diagnosis of the S. aureus bacteraemia).
Echocardiograms were analysed by two cardiologists 
independently and the size of vegetations measured in at 
least two views using the calliper tool. A mean of the largest 
dimensions was used as the ﬁ nal vegetation size. 
Statistical analyses
Data were analysed using Microsoft Excel 2010 (Microsoft, 
Redmond, WA, USA) and R 3.2.2 (R Foundation for Statistical 
Computing, Vienna, Austria). Continuous data are presented 
as medians and interquartile ranges and were analysed using 
a Mann–Whitney U-test. Categorical data are presented as 
numbers and percentages and were analysed using Fisher’s 
exact test. Spearman’s rank-order correlation test using 
the Spearman’s correlation coefficient was applied for 
correlations between continuous variables. 
Ethical approval
Advice was sought from the South East Scotland Research 
Ethics Service regarding access to patient information. As this 
study was based on data obtained in the course of routine 
patient care, with no communication of identiﬁ able patient 
data, no formal ethical review was required. All patient-related 
data was handled in accordance with Caldicott principles.
Results 
A total of 15 PWID and 14 non-PWID with S. aureus IE were 
included in the study. All PWID gave a history of having injected 
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NPS substances (ethylphenidate, also known as ‘Burst’) prior 
to their presentation. Three PWID described concomitant 
heroin and NPS use immediately prior to presentation, with 
the rest describing NPS use only. Of this group, eight had 
previous, but not recent, exposure to heroin. No cases of 
IE were identiﬁ ed amongst PWID with exclusive heroin use 
in the time period examined. The median age of PWID was 
signiﬁ cantly lower than of non-PWID (36 [interquartile range 
(IQR): 33–40] vs 66 [IQR: 64–77] years; p = 8.0 × 10-7). 
A total of 87% of PWID and 57% of non-PWID were male. 
All patients in the PWID group were HIV negative and three 
were hepatitis C negative. Two PWIDs had a new diagnosis 
of hepatitis C and all the others had chronic hepatitis C. 
The demographic characteristics and blood markers for all 
patients are summarised in Table 1.
In the PWID group, there were eight (53.3%) patients with 
echocardiographic evidence of vegetations solely on the 
tricuspid valve, two (13.3%) with sole mitral valve involvement, 
one (6.7%) patient with sole aortic valve involvement, one 
(6.7%) patient with both tricuspid and pulmonary valve 
involvement, and three (20%) patients with both mitral and 
tricuspid valve vegetations. In contrast, exclusively left-sided 
heart valves were involved in the non-PWID group: mitral 
valve, n = 10 (71.4%); aortic valve, n = 4 (28.6%).
The vegetation dimensions on echocardiogram were 
signiﬁ cantly greater in the PWID group than in the non-PWID 
group [median: 1.7 (IQR: 1.5–2.0) vs 0.65 (IQR: 0.20–
1.10) cm; p = 0.009], as summarised in Figure 1. There 
was an inverse correlation between vegetation size and 
albumin levels (Spearman’s rank correlation rho: -0.42; p = 
0.037) (Figure 2); however, vegetation size did not correlate 
with other blood markers, including C-reactive protein (CRP; 
rho = 0.30; p = 0.13). 
Embolic complications secondary to infective endocarditis 
were more common in the PWID group [15 (100%) PWID and 
1 (7.1%) non-PWID; p = 2.1 x 10-7]. 
A total of 12 (80%) patients in the PWID group had 
pulmonary emboli, of which four (26.7%) had CT evidence 
of both pulmonary and extrapulmonary emboli (e.g. splenic, 
renal and cerebral emboli) and three (20%) patients had 
extrapulmonary involvement only. In contrast, no pulmonary 
emboli were seen in the non-PWID group and only one 
patient had extrapulmonary emboli. Vegetation size was 
available for all the PWID-associated cases of S. aureus 
IE but only for 13 (92.8%) of the non-PWID cases. A 
vegetation size of ≥10 mm (n = 18) was associated with a 
higher number of embolic complications than with smaller 
vegetations (≤10 mm, n = 10; number with emboli, 15 vs 
1, respectively; p = 2.7 × 10-4). Furthermore, in patients 
with small vegetations only one had embolic phenomena 
and this was an NPS user. A total of ﬁ ve PWIDs had lung 
abscesses, four had brain abscesses, three had splenic 
abscesses and ﬁ ve patients had no deep collections. 
There were no reported abscesses in the non-PWID group. 
For all the PWID patients with lung abscesses, there was 
evidence of tricuspid valve infection. The abscesses were 
predominantly basal and commonly in the right lung, 
although in one patient they were bilateral.
One patient required bilateral amputation of his feet that 
were infected and necrotic as a consequence of septic 
emboli in order to facilitate control of secondary sites of 
active infection and bacteraemia to optimise the chance of 
successful valve replacement surgery. Lung, brain and spleen 
abscesses were treated conservatively with antimicrobials 
and did not require drainage procedures. Three patients in 
the PWID group required valve surgery compared to seven in 
the non-PWID group (p = 0.13). 
There was no signiﬁ cant difference in median CRP values 
between PWID and non-PWID groups [266 (IQR: 230–300) 
vs 190 (IQR: 135–333) mg/l; p = 0.23]; however, albumin 
was signiﬁ cantly lower in the PWID group than in the non-
PWID group at the time of diagnosis of IE [18 (IQR: 16–21) 
vs 26 (IQR: 23–28) g/l; p = 0.002].
Demographics PWID
Median (IQR)
Non-PWID
Median (IQR)
p-value
Total (n) 15 14 –
 Age (years) 36 (33–40) 66 (64–77) 8.0 × 10-7
Gender (male : female) 13 : 2 8 : 6 0.109
CRP (mg/l) 266 (230–300) 190 (135–333) 0.232
Albumin (g/l) 18.0 (16.0–21.0) 26.0 (23.0–28.0) 0.002
WCC (109/l) 15.2 (13.5–17.9) 11.8 (9.9–14.7) 0.247
Haemoglobin (mg/dl) 104.4 (97.8–114.0) 115.0 (95.0–139.8) 0.262
Vegetation size (cm) 1.7 (1.5–2.0) 0.65 (0.2–1.1) 0.009
Embolic complications 15 1 2.1 x 10-7
Required valve surgery 3 7 0.13
Mortality at 30 days 1 0 1.00
Mortality at 90 days 2 4 0.39
CRP: C-reactive protein; IQR: interquartile range; WCC: white blood cell count
Table 1 Demographic details, blood parameters and vegetation size for the persons who inject drugs (PWID) and non-PWID groups
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Although all the PWID IE cases were due to methicillin-
susceptible S. aureus, a range of subtypes were identiﬁ ed 
(spa types t062, t084, t127, t131, t267, t571, t605, t1509, 
t1548, t3609 and t8272). All isolates were negative for the 
gene coding the Panton–Valentine leukocidin toxin. 
There was one death at 30 days in the PWID group. At 
90 days there were four deaths in the non-PWID group and 
two in the PWID group, which, owing to the relatively small 
numbers, was not statistically signiﬁ cant (p = 0.39).
Discussion
While there is a well-established association between 
injecting recreational drugs and IE, the incidence of IE in 
PWID is considered low at 1.5–20 cases of endocarditis per 
1,000 person-years.38 In our study, we identiﬁ ed 15 cases 
of bacterial endocarditis in PWID within 28 months and this 
correlated with a period of intense NPS injecting behaviour 
in our healthcare region. This dramatic increase in cases 
impacted on local healthcare services, including cardiology, 
cardiothoracic surgery, orthopaedic surgery, vascular 
surgery, plastic surgery, general surgery, critical care, 
infectious diseases and microbiology. During our period of 
prospective surveillance of cases of S. aureus IE in PWID 
from 2014 to 2015 there were no cases of IE identiﬁ ed in 
exclusive heroin injectors who did not inject NPS, suggesting 
a strong association between injecting NPS and the risk of 
subsequent S. aureus IE. It is plausible that the pattern of IE 
seen in our cohort of patients was substance speciﬁ c, linked 
to NPS and not heroin. During this period, NPS injecting 
was dominated by ethylphenidate-based substances that 
were sold legally with names such as ‘Burst’, ‘Blue Stuff’, 
‘Blue’ and ‘Quack.’
Possible explanations for this apparent association with 
NPS injecting are complex. Often NPS injectors exhibited 
increased daily frequency of injecting (compared to opiate 
injectors) leading to increased probability of bacteraemia 
through many more skin punctures per day. A preferred 
anatomical site for injecting was the groin, which is an area 
where S. aureus may be commensal ﬂ ora that could facilitate 
the direct inoculation of S. aureus into the bloodstream. 
Once in the bloodstream there is an opportunity for 
S. aureus to attach to heart valves. Another difference in 
NPS use was the practice of injecting from communal pots, 
and NPS was not heated or dissolved in citric acid unlike 
heroin.39 Multiple areas of necrotic-looking skin lesions 
Figure 1 Differences in 
vegetation size at 
echocardiogram in patients 
who injected intravenous (IV) 
new psychoactive substances 
(NPS) vs those who did not 
inject drugs. PWID: persons 
who inject drugs
Figure 2 Correlation between 
albumin levels and vegetation 
size at echocardiogram
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(Figure 3) were characteristic of ethylphenidate-based 
NPS injecting resulting in multiple skin sites of potential 
entry of S. aureus to bloodstream. These may have arisen 
owing to residual particulate matter in injected NPS that 
may have caused vascular damage and local necrosis. 
Extravasated NPS solutions are often corrosive to soft 
tissue and this may facilitate entry of commensal skin 
organisms, such as S. aureus, again from superﬁ cial skin 
damage with progression to deeper soft tissue infection or 
bacteraemia.34 A direct cardiac toxic effect of ‘bath salts’ on 
heart valves is also a possibility, leading to deposition of an 
adulterant on cardiac valves that could facilitate attachment 
of S. aureus.17 Other factors linked to NPS use could include 
S. aureus contamination of the drug solution, which, unlike 
heroin, does not require heating prior to injecting, thus 
increasing the chance of S. aureus survival in the injected 
drug solution. 
The range of spa types of S. aureus suggests that the 
organisms may have been arising from the individual 
commensal ﬂ ora of the affected PWID, although there were 
three cases of t127, two cases of t131 and two cases 
of t605, which might indicate a link between cases and 
possible person-to-person transmission or infection from 
the same source. No epidemiological links were known 
that might account for such transmission and it should be 
recognised that these are common spa types in the UK 
and may have arisen through coincidence. Although there 
is a clear association between NPS use and S. aureus IE, 
the clinical features of the IE differ between PWID and non-
PWID groups. S. aureus IE in NPS users was associated 
with larger valve vegetations and significant embolic 
phenomena complicating both antimicrobial and surgical 
management. This was because the presence of concurrent 
deep abscesses needed to be taken into consideration 
when planning the timing of valve replacement, the need 
for drainage and the duration of intravenous antibiotic 
treatment. In addition, the coexistence of deep organ 
abscesses caused by embolism of infected material was 
considered to present a risk of S. aureus reinfection to 
newly placed valve replacements inserted as emergency 
procedures owing to native valve failure. The larger size of 
vegetations seen in the PWID group may explain the higher 
incidence of embolic complications in the NPS users as 
a larger vegetation may be more able to release bacteria 
into blood given its larger surface area. Studies report 
that in patients with left-sided native-valve IE, the risk of 
embolism is increased with a vegetation size ≥10 mm.40,41 
We found a similar increased risk of embolic complications 
in patients with a vegetation size ≥10 mm, although this 
is not restricted to left-sided IE in the NPS injecting PWID 
population where a new pattern of left-sided IE is emerging 
in PWID.42,43 This is consistent with our ﬁ ndings of IE in 
right- and left-sided valves in the PWID group. 
The tricuspid valve is most frequently involved in opiate 
injectors and left-sided valvular involvement is uncommon.42,43 
We here report a new pattern of valve involvement in NPS 
injectors with exclusive left-sided valve involvement in 3/15 
(20%) and a further 3/15 with both mitral and tricuspid 
involvement at presentation. 
There is interest in identifying biomarkers to predict 
outcomes in patients with infective endocarditis.44,45 It has 
been shown that detecting a high CRP and low albumin within 
48 hours of admission is associated with higher mortality 
rates from IE.44 Patients with IE-associated emboli have 
also been reported to have higher CRP and lower albumin 
levels.45 Although a small cohort, we also found that in PWID 
with NPS-associated IE there was an association between 
a lower albumin and increased incidence of embolic events 
but not increased mortality. We also identiﬁ ed a moderate 
negative correlation between albumin levels and vegetation 
size, another factor that has been shown to predict embolic 
risk in IE.45 
IE caused by S. aureus is associated with a less favourable 
prognosis in a non-PWID population than in a PWID 
population.46 In our study, despite a greater embolic risk, we 
observed a lower 90 day mortality in the PWID group than 
in the non-PWID population. The higher median age of the 
non-PWID group could be inﬂ uencing the higher mortality, 
possibly as a consequence of comorbidities associated with 
increased age.46
Our study has certain limitations. Firstly, we compared 
a prospective case series with a retrospective cohort 
of endocarditis and the patient cohorts were small. 
There were no prospective cases of non-PWID S. aureus 
IE recorded during the study period. In order to identify 
Figure 3 Skin lesions observed in a person who injected 
drugs (PWID) with new psychoactive substances S. aureus 
infective endocarditis (IE). Multiple necrotic lesions located 
in the peripheries of digits that resemble embolic 
phenomena were commonly seen in PWID with S. aureus 
IE. Similar such lesions, however, were also observed in 
PWID in other anatomical locations and in PWID who did 
not have a diagnosis of IE and so may not be speciﬁ c to 
S. aureus IE
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a similar number of cases of S. aureus IE in non-PWID 
patients we had to screen medical records covering a 9-year 
period, illustrating how much more common S. aureus 
IE had become in the NPS-injecting PWID population. 
Secondly, the groups compared differed in their age, which 
may inﬂ uence the outcomes seen. However, it is worth 
noting that S. aureus endocarditis in the non-injecting 
population is very rare and there were no cases of non-
NPS endocarditis identiﬁ ed during the study period. Septic 
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legally available resulted in a clear impact on the clinical 
presentation of PWID S. aureus IE requiring the expertise of 
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associated morbidity. Interestingly, in the months since trade 
in NPS was rendered illegal by the Psychoactive Substances 
Act 2016, there has been a reduction in cases of PWID-
associated S. aureus infection locally. 
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